Antiplatelet pretreatment and outcomes in intravenous thrombolysis for stroke: a systematic review and meta-analysis
Recommended Citation
Tsivgoulis G, Katsanos AH, Zand R, Sharma VK, Kohrmann M, Giannopoulos S, Dardiotis E, Alexandrov AW, Mitsias PD, Schellinger PD, and Alexandrov AV. Antiplatelet pretreatment and outcomes in intravenous thrombolysis for stroke: a systematic review and meta-analysis. J Neurol 2017; 264(6):1227-1235.
Document Type
Article
Publication Date
6-1-2017
Publication Title
Journal of neurology
Abstract
Since there are contradictory data regarding the association of antiplatelet pretreatment (AP) with safety and efficacy outcomes of intravenous thrombolysis (IVT) for acute ischemic stroke (AIS), we conducted a systematic review and meta-analysis of available randomized-controlled clinical trials (RCTs) to investigate the association of AP with outcomes of AIS patients treated with intravenous alteplase. The outcome events of interest included symptomatic intracranial hemorrhage (sICH), fatal ICH, complete recanalization (CR), 3-month favorable functional outcome (FFO, mRS score 0-1), 3-month functional independence (FI, mRS score 0-2), and mortality. The corresponding odds ratios (ORs) were calculated for all the outcome events using random-effects model. The adjusted age and admission NIHSS OR (ORadjusted) were also estimated for all available outcomes. We included 7 RCTs (4376 patients, 33.7% with AP). In unadjusted analyses, AP was associated with higher likelihood of sICH (OR = 1.89, 95% CI 1.40-2.56), death (OR = 1.59, 95% CI 1.24-2.03), and lower likelihood of 3-month FI (OR = 0.69, 95% CI 0.56-0.85). No association was detected between AP and fatal ICH (OR = 1.53, 95% CI 0.75-3.15), 3-month FFO (OR = 0.79, 95% CI 0.58-1.07), and CR (OR = 0.64, 95% CI 0.04-11.66). After adjustment for age and admission stroke severity, AP was not related to sICH (ORadjusted = 1.67, 95% CI 0.75-3.72), 3-month FI (ORadjusted = 0.88, 95% CI 0.54-1.42), or death (ORadjusted = 1.01, 95% CI 0.55-1.86) in adjusted analyses. In conclusion, after adjusting for confounders, AP was not associated with a higher risk of sICH and worse 3-month functional outcome in AIS treated with intravenous alteplase. Antiplatelet intake prior to tPA-bolus should not be used as a reason to withhold or lower alteplase dose in AIS patients treated with IVT.
Medical Subject Headings
Administration, Intravenous; Databases, Bibliographic; Humans; Intracranial Hemorrhages; Platelet Aggregation Inhibitors; Stroke; Thrombolytic Therapy; Treatment Outcome
PubMed ID
28550481
Volume
264
Issue
6
First Page
1227
Last Page
1235
